Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28050241 | 0.78 | RAB9A (0.68) | CYP3A4LMNARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL28728369 | 0.76 | RAB9A (0.66) | CYP3A4LMNARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL14628665 | 0.76 | ADORA2A (0.57) | LMNARAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL29647608 | 0.75 | CYP3A4 (0.61) | CYP3A4LMNARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL29502497 | 0.75 | LMNA (0.61) | CYP3A4LMNARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1800355 | 0.75 | CYP3A4 (0.61) | CYP3A4LMNARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL19538202 | 0.75 | RAB9A (0.56) | CYP3A4LMNARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL14380967 | 0.75 | CYP3A4 (0.61) | CYP3A4LMNARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2016737 | 0.75 | LMNA (0.61) | CYP3A4LMNARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1488094 | 0.75 | BCHE (0.57) | CYP3A4LMNARAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2896613-B1 | SULFONAMIDE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9540360-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9487488-B2 | Sulfonamide compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-11-08 | — | — | US | disclosed |
| CN-103443080-B | There is the sulfonamide compounds of TRPM8 antagonistic activity | 田边三菱制药株式会社 | 2016-10-12 | — | — | CN | disclosed |
| EP-2686302-B1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-20150307454-A1 | Sulfonamide Compound | KALLYOPE, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| EP-2896613-A1 | SULFONAMIDE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-07-22 | — | — | EP | disclosed |
| US-8987445-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20140005393-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | KALLYOPE, INC. | 2014-01-02 | — | — | US | disclosed |
| CN-103443080-A | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORP | 2013-12-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | TRPM8, TRPM7, TRPM2 | CYP3A4 1812/4885LMNA 1768/4885RAB9A 2011/4885 |
| US-20140005393-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | TRPM8, TRPM7, TRPM2 | CYP3A4 1792/4885LMNA 1920/4885RAB9A 1931/4885 |
| US-20150307454-A1 | Sulfonamide Compound | TRPM8, TRPM5, TRPM7 | CYP3A4 1795/4885LMNA 4357/4885RAB9A 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.